ArticlePharmacoEconomics2010

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Josephine Mauskopf et al.PubMed ↗Publisher ↗

No numbers read from the abstract.